Drugs / TH-4000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02454842 | Jun 2015 → Jan 2017 | non-small cell lung carcinoma | Rain Oncology Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TH-4000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02454842 ↗ |
| Known as | Tarloxotinib | “TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug” NCT02454842 ↗ |
| Modality | Other / unclassified | “TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug” NCT02454842 ↗ |
| Route | Intravenous | “will be administered by IV infusion” NCT02454842 ↗ |